See more : IVF Hartmann Holding AG (VBSN.SW) Income Statement Analysis – Financial Results
Complete financial analysis of Aptorum Group Limited (APM) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Aptorum Group Limited, a leading company in the Biotechnology industry within the Healthcare sector.
- BHP Group Limited (BLT.SW) Income Statement Analysis – Financial Results
- Computershare Limited (CMSQF) Income Statement Analysis – Financial Results
- Zeal Aqua Limited (ZEAL.BO) Income Statement Analysis – Financial Results
- Giglio Group S.p.A. (GG.MI) Income Statement Analysis – Financial Results
- Thunder Mountain Gold, Inc. (THMG) Income Statement Analysis – Financial Results
Aptorum Group Limited (APM)
About Aptorum Group Limited
Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 431.38K | 1.30M | 1.54M | 911.51K | 535.17K | 383.45K | 0.00 |
| Cost of Revenue | 420.81K | 1.22M | 1.46M | 1.02M | 794.55K | 318.01K | 58.90K |
| Gross Profit | 10.57K | 80.07K | 81.85K | -103.51K | -259.38K | 65.44K | -58.90K |
| Gross Profit Ratio | 2.45% | 6.18% | 5.31% | -11.36% | -48.47% | 17.07% | 0.00% |
| Research & Development | 5.20M | 9.22M | 10.87M | 11.59M | 6.94M | 3.10M | 2.50M |
| General & Administrative | 4.37M | 7.87M | 7.70M | 7.71M | 10.78M | 6.73M | 0.00 |
| Selling & Marketing | 48.98K | 98.08K | 95.95K | 55.43K | 0.00 | 0.00 | 0.00 |
| SG&A | 4.41M | 7.97M | 7.80M | 7.71M | 10.78M | 6.73M | 2.88M |
| Other Expenses | -9.60M | 404.54K | 623.64K | 877.39K | 220.89K | 560.71K | -257.18K |
| Operating Expenses | 10.57K | 17.59M | 19.29M | 20.17M | 17.94M | 10.39M | 5.63M |
| Cost & Expenses | 10.95M | 18.81M | 20.75M | 21.19M | 18.73M | 10.71M | 5.69M |
| Interest Income | 0.00 | 146.59K | 0.00 | 0.00 | 0.00 | 0.00 | 44.27K |
| Interest Expense | 121.15K | 146.59K | 93.60K | 243.63K | 3.70M | 4.46M | 0.00 |
| Depreciation & Amortization | 1.13M | 1.21M | 1.19M | 1.33M | 1.30M | 682.29K | 58.90K |
| EBITDA | -9.60M | -17.59M | -19.29M | 6.50M | -15.12M | -9.99M | -2.50M |
| EBITDA Ratio | -2,225.19% | -1,678.81% | -1,158.95% | -2,034.44% | -3,443.92% | -2,424.73% | 0.00% |
| Operating Income | -10.52M | -22.96M | -19.06M | -19.88M | -19.73M | -10.33M | -5.69M |
| Operating Income Ratio | -2,439.47% | -1,771.99% | -1,236.31% | -2,180.86% | -3,686.76% | -2,693.47% | 0.00% |
| Total Other Income/Expenses | 6.18M | 6.06M | -7.91M | 25.20M | -1.92M | -4.81M | 3.13M |
| Income Before Tax | -4.34M | -11.53M | -27.11M | 4.92M | -20.12M | -15.13M | -2.56M |
| Income Before Tax Ratio | -1,006.30% | -889.36% | -1,758.64% | 539.78% | -3,759.01% | -3,946.93% | 0.00% |
| Income Tax Expense | 0.00 | -6.21M | -1.83M | -1.51M | 737.64K | -302.76K | -14.05K |
| Net Income | -2.82M | -5.31M | -25.29M | 7.07M | -20.85M | -14.83M | -2.55M |
| Net Income Ratio | -654.80% | -410.10% | -1,640.21% | 775.29% | -3,896.84% | -3,867.97% | 0.00% |
| EPS | -0.62 | -14.89 | -7.22 | 2.03 | -7.19 | -5.31 | -0.85 |
| EPS Diluted | -0.62 | -14.89 | -7.22 | 2.00 | -7.19 | -5.31 | -0.85 |
| Weighted Avg Shares Out | 4.52M | 356.95K | 3.50M | 3.11M | 2.90M | 2.79M | 3.01M |
| Weighted Avg Shares Out (Dil) | 4.52M | 356.95K | 3.50M | 3.15M | 2.90M | 2.79M | 3.01M |
Instana Announces Integration with Coralogix Log Analytics Solution
New Relic Announces The General Availability Of AIOps Platform
Aptorum Group Ltd (NASDAQ:APM) Sees Significant Growth in Short Interest
Aptorum Group Limited to Present at the Planet MicroCap Showcase Virtual Investor Conference 2020
Solebury Trout Announces Additional Virtual Conference Presentations from Life Science Companies on April 7, 2020
知臨集団がCovar Pharmaceuticalsと協業して既存のSmart-ACT™プラットフォームおよびActicule感染性疾患プラットフォームを基盤に2019年コロナウイルス疾患（COVID-19）対策のための最低3種のリパーパシング薬候補（SACT-COV19）を研究
Az Aptorum Csoport egyttműkdik a Covar Pharmaceuticals-zel
Firma Aptorum Group spolupracuje se společnost Covar Pharmaceuticals při hledn a otestovn nejmně 3 vhodnch kandidtnch ltek (SACT-COV19) na lčbu onemocněn COVID-19, a to s využitm platforem Smart-ACTTM Acticule Infectious Disease
知臨集團與Covar醫療攜手透過現有Smart-ACT™平臺和Acticule傳染病平臺研究至少3種2019冠狀病毒肺炎(COVID-19)候選再利用藥物（SACT-COV19）
Source: https://incomestatements.info
Category: Stock Reports